The Centers for Medicare and Medicaid Services finalized a 2.48% average payment increase for Medicare Advantage plans in 2027, translating to over $13 billion in additional revenue for insurers. The decision marks a dramatic reversal from CMS's January proposal of just 0.09%, sending shares of Humana up 12%, UnitedHealth Group up 10%, CVS Health up 9%, and Elevance Health up 6% in after-hours trading.
The boost is a major relief for an industry battered by rising medical utilization among seniors and shrinking profit margins. When factoring in estimated risk score trends from population changes and coding practices, the effective increase reaches 4.98%. CMS also delayed updates to its risk adjustment model, using the 2024 model calibrated with 2018 diagnoses and 2019 expenditure data instead.
Analysts note this is the most favorable Medicare Advantage rate decision in years, potentially stabilizing an industry that saw billions in losses from higher-than-expected medical costs in 2025. The combined market cap of the top five health insurers gained roughly $50 billion on the announcement.
